WM
MCID: WLD007
MIFTS: 63

Waldenstroem's Macroglobulinemia (WM)

Categories: Blood diseases, Cancer diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Waldenstroem's Macroglobulinemia

MalaCards integrated aliases for Waldenstroem's Macroglobulinemia:

Name: Waldenstroem's Macroglobulinemia 12 15
Waldenstrom Macroglobulinemia 12 20 43 58 54 44 39 17
Macroglobulinemia of Waldenstrom 20 43
Lymphoplasmacytic Lymphoma with Igm Gammopathy 12
Waldenstrom's Macroglobulinaemia 20
Waldenström's Macroglobulinemia 74
Waldenstrom's Macroglobulinemia 43
Waldenström Macroglobulinemia 43
Lymphoplasmacytic Lymphoma 20
Waldenstrom's Syndrome 20
Wm 43

Characteristics:

Orphanet epidemiological data:

58
waldenstrom macroglobulinemia
Inheritance: Multigenic/multifactorial; Prevalence: 1-9/1000000 (Europe),1-9/100000 (France),1-9/1000000 (United States),1-9/1000000 (United Kingdom),1-9/1000000 (Spain),1-9/100000 (Europe); Age of onset: Elderly; Age of death: elderly;

Classifications:

Orphanet: 58  
Rare neurological diseases
Rare haematological diseases


Summaries for Waldenstroem's Macroglobulinemia

MedlinePlus Genetics : 43 Waldenström macroglobulinemia is a rare blood cell cancer characterized by an excess of abnormal white blood cells called lymphoplasmacytic cells in the bone marrow. This condition is classified as a lymphoplasmacytic lymphoma. The abnormal cells have characteristics of both white blood cells (lymphocytes) called B cells and of more mature cells derived from B cells known as plasma cells. These abnormal cells produce excess amounts of IgM, a type of protein known as an immunoglobulin; the overproduction of this large protein is how the condition got its name ("macroglobulinemia").Waldenström macroglobulinemia usually begins in a person's sixties and is a slow-growing (indolent) cancer. Some affected individuals have elevated levels of IgM and lymphoplasmacytic cells but no symptoms of the condition; in these cases, the disease is usually found incidentally by a blood test taken for another reason. These individuals are diagnosed with smoldering (or asymptomatic) Waldenström macroglobulinemia. It can be several years before this form of the condition progresses to the symptomatic form.Individuals with symptomatic Waldenström macroglobulinemia can experience general symptoms such as fever, night sweats, and weight loss. Several other signs and symptoms of the condition are related to the excess IgM, which can thicken blood and impair circulation, causing a condition known as hyperviscosity syndrome. Features related to hyperviscosity syndrome include bleeding in the nose or mouth, blurring or loss of vision, headache, dizziness, and difficulty coordinating movements (ataxia). In some affected individuals, the IgM proteins clump together in the hands and feet, where the body temperature is cooler than at the center of the body. These proteins are then referred to as cryoglobulins, and their clumping causes a condition known as cryoglobulinemia. Cryoglobulinemia can lead to pain in the hands and feet or episodes of Raynaud phenomenon, in which the fingers and toes turn white or blue in response to cold temperatures. The IgM protein can also build up in organs such as the heart and kidneys, causing a condition called amyloidosis, which can lead to heart and kidney problems. Some people with Waldenström macroglobulinemia develop a loss of sensation and weakness in the limbs (peripheral neuropathy). Doctors are unsure why this feature occurs, although they speculate that the IgM protein attaches to the protective covering of nerve cells (myelin) and breaks it down. The damaged nerves cannot carry signals normally, leading to neuropathy.Other features of Waldenström macroglobulinemia are due to the accumulation of lymphoplasmacytic cells in different tissues. For example, accumulation of these cells can lead to an enlarged liver (hepatomegaly), spleen (splenomegaly), or lymph nodes (lymphadenopathy). In the bone marrow, the lymphoplasmacytic cells interfere with normal blood cell development, causing a shortage of normal blood cells (pancytopenia). Excessive tiredness (fatigue) due to a reduction in red blood cells (anemia) is common in affected individuals.People with Waldenström macroglobulinemia have an increased risk of developing other cancers of the blood or other tissues.

MalaCards based summary : Waldenstroem's Macroglobulinemia, also known as waldenstrom macroglobulinemia, is related to lymphoplasmacytic lymphoma and lymphoma. An important gene associated with Waldenstroem's Macroglobulinemia is MYD88 (MYD88 Innate Immune Signal Transduction Adaptor), and among its related pathways/superpathways are Immune response NFAT in immune response and T cell receptor signaling pathway. The drugs Chlorambucil and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, b cells and heart, and related phenotypes are leukemia and lymphoma

Disease Ontology : 12 A lymphoplasmacytic lymphoma characterized by the accumulation of monoclonal cells in the bone marrow and peripheral lymphoid tissues, and associated with the production of serum immunoglobulin M (IgM) monoclonal protein.

GARD : 20 Waldenstrom macroglobulinemia is a chronic, slow-growing lymphoproliferative disorder. It usually affects older adults and is primarily found in the bone marrow, although lymph nodes and the spleen may be involved. Affected individuals have a high level of an antibody called immunoglobulin M (IgM) in their blood, which can cause thickening of the blood (hyperviscosity). Although some individuals initially do not have symptoms and are diagnosed from routine blood work, common symptoms may include weakness, appetite loss and weight loss. Other symptoms may include peripheral neuropathy, fever, Raynaud's phenomenon, and mental status changes. Hyperviscosity of the blood may cause nosebleeds, headaches, dizziness, and blurring or loss of vision. The cause of the condition is not known but environmental, genetic, and viral factors have been suggested. There have been some reports of familial cases suggesting a genetic predisposition. Treatment is often reserved for those with symptoms and may include various medications including corticosteroids, alkylating agents, biologic response modifiers and purine analogues.

Wikipedia : 74 Waldenström's macroglobulinemia (/ˈvældənstrɛmz ˌmækroʊˌɡlɒbjələˈniːmiə/; WM) is a type of cancer... more...

Related Diseases for Waldenstroem's Macroglobulinemia

Diseases related to Waldenstroem's Macroglobulinemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 483)
# Related Disease Score Top Affiliating Genes
1 lymphoplasmacytic lymphoma 33.0 PAX5 MYD88 CD40LG BTK
2 lymphoma 31.3 PTPRC PAX5 MYD88 MS4A1 IRF4 CCND1
3 macroglobulinemia 31.2 PAX5 MYD88 HAS1 CD40LG CD40 BTK
4 marginal zone b-cell lymphoma 30.6 PAX5 MYD88 IRF4 CD40LG CCND1 BTK
5 bone lymphoma 30.5 PTPRC IRF4
6 lymphoma, hodgkin, classic 30.5 PTPRC PAX5 MS4A1 MIR155 IRF4 CD40
7 cll/sll 30.4 ZAP70 PAX5 CCND1 BTK
8 agammaglobulinemia 30.4 CD40LG CD40 BTK
9 follicular lymphoma 30.4 MS4A1 MIR155 IRF4 CD40 CCND1
10 richter's syndrome 30.4 ZAP70 IRF4 BTK
11 plasmacytoma 30.4 PTPRC PAX5 IRF4 CCND1
12 myeloid sarcoma 30.4 PTPRC PAX5 IRF4
13 toxoplasmosis 30.3 MYD88 CD40LG CD40
14 diffuse large b-cell lymphoma 30.3 PTPRC PAX5 MYD88 MIR155 IRF4 CD40
15 splenic marginal zone lymphoma 30.3 PAX5 CD40 BTK BIRC3
16 gastrointestinal lymphoma 30.2 CCND1 BIRC3
17 monoclonal gammopathy of uncertain significance 30.2 PTPRC MYD88 MAG IRF4 CCND1
18 plasma cell leukemia 30.2 IRF4 CD40 CCND1
19 leukemia, acute myeloid 30.2 PTPRC PAX5 MIR9-1 MIR184 MIR155 CCND1
20 b-cell lymphoma 30.2 ZAP70 PTPRC PAX5 MYD88 MS4A1 MIR155
21 peripheral t-cell lymphoma 30.1 PTPRC MS4A1 CCND1
22 combined immunodeficiency 30.0 ZAP70 PTPRC IRF4 CD40LG CD40
23 burkitt lymphoma 29.9 PAX5 MS4A1 MIR155 IRF4 CD40LG CD40
24 inflammatory bowel disease 29.9 PTPRC MYD88 MIR155 CD40LG CD40 CCND1
25 peripheral nervous system disease 29.9 PTPRC MIR9-1 MIR542 MAG CCND1
26 mature b-cell neoplasm 29.8 PTPRC PAX5 MIR9-1 MIR155 IRF4 CD40
27 lymphoma, mucosa-associated lymphoid type 29.8 ZAP70 PTPRC PAX5 MYD88 IRF4 CD40
28 myeloma, multiple 29.8 PTPRC MYD88 MIR9-1 IRF4 CD40 CCND1
29 mantle cell lymphoma 29.6 PTPRC PAX5 MIR155 CD40LG CD40 CCND1
30 lymphoma, non-hodgkin, familial 29.6 PTPRC PAX5 MYD88 MS4A1 MIR9-1 MIR155
31 leukemia, acute lymphoblastic 29.4 ZAP70 PTPRC PAX5 MIR9-1 MIR155 IRF4
32 leukemia, chronic lymphocytic 29.2 ZAP70 PTPRC PAX5 MYD88 MS4A1 MIR9-1
33 lymphoplasmacytic lymphoma without igm production 11.3
34 macroglobulinemia, waldenstrom 1 11.2
35 light chain deposition disease 11.2
36 primary cutaneous diffuse large b-cell lymphoma, leg type 10.4 MYD88 IRF4
37 light fixation seizure syndrome 10.4 CD40LG CD40
38 geotrichosis 10.4 CD40LG CD40
39 sulfamethoxazole allergy 10.4 CD40LG CD40
40 immunodeficiency with hyper-igm, type 4 10.4 CD40LG CD40
41 breast lipoma 10.4 PTPRC PAX5
42 b cell prolymphocytic leukemia 10.3 ZAP70 MS4A1
43 epiglottis neoplasm 10.3 PTPRC CCND1
44 leukemia, chronic lymphocytic 2 10.3 ZAP70 MS4A1
45 primary cutaneous anaplastic large cell lymphoma 10.3 PTPRC IRF4
46 tracheal lymphoma 10.3 PAX5 CCND1
47 inflammatory bowel disease 16 10.3 CD40LG CD40
48 immunodeficiency with hyper-igm, type 2 10.3 PAX5 CD40LG CD40
49 cd45 deficiency 10.3 ZAP70 PTPRC
50 splenomegaly 10.3

Graphical network of the top 20 diseases related to Waldenstroem's Macroglobulinemia:



Diseases related to Waldenstroem's Macroglobulinemia

Symptoms & Phenotypes for Waldenstroem's Macroglobulinemia

Human phenotypes related to Waldenstroem's Macroglobulinemia:

58 31 (show all 45)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 leukemia 58 31 hallmark (90%) Very frequent (99-80%) HP:0001909
2 lymphoma 58 31 hallmark (90%) Very frequent (99-80%) HP:0002665
3 monoclonal immunoglobulin m proteinemia 58 31 hallmark (90%) Very frequent (99-80%) HP:0005508
4 respiratory insufficiency 58 31 frequent (33%) Frequent (79-30%) HP:0002093
5 pallor 58 31 frequent (33%) Frequent (79-30%) HP:0000980
6 vertigo 58 31 frequent (33%) Frequent (79-30%) HP:0002321
7 gingival bleeding 58 31 frequent (33%) Frequent (79-30%) HP:0000225
8 abnormality of neutrophils 58 31 frequent (33%) Frequent (79-30%) HP:0001874
9 hypercoagulability 58 31 frequent (33%) Frequent (79-30%) HP:0100724
10 normocytic anemia 58 31 frequent (33%) Frequent (79-30%) HP:0001897
11 ataxia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001251
12 hearing impairment 58 31 occasional (7.5%) Occasional (29-5%) HP:0000365
13 splenomegaly 58 31 occasional (7.5%) Occasional (29-5%) HP:0001744
14 hepatomegaly 58 31 occasional (7.5%) Occasional (29-5%) HP:0002240
15 malabsorption 58 31 occasional (7.5%) Occasional (29-5%) HP:0002024
16 reduced consciousness/confusion 58 31 occasional (7.5%) Occasional (29-5%) HP:0004372
17 fatigue 58 31 occasional (7.5%) Occasional (29-5%) HP:0012378
18 renal insufficiency 58 31 occasional (7.5%) Occasional (29-5%) HP:0000083
19 fever 58 31 occasional (7.5%) Occasional (29-5%) HP:0001945
20 cranial nerve paralysis 58 31 occasional (7.5%) Occasional (29-5%) HP:0006824
21 congestive heart failure 58 31 occasional (7.5%) Occasional (29-5%) HP:0001635
22 abnormal retinal vascular morphology 58 31 occasional (7.5%) Occasional (29-5%) HP:0008046
23 anorexia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002039
24 proptosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000520
25 purpura 58 31 occasional (7.5%) Occasional (29-5%) HP:0000979
26 gastrointestinal hemorrhage 58 31 occasional (7.5%) Occasional (29-5%) HP:0002239
27 stroke 58 31 occasional (7.5%) Occasional (29-5%) HP:0001297
28 periorbital edema 58 31 occasional (7.5%) Occasional (29-5%) HP:0100539
29 peripheral neuropathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0009830
30 epistaxis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000421
31 migraine 58 31 occasional (7.5%) Occasional (29-5%) HP:0002076
32 urticaria 58 31 occasional (7.5%) Occasional (29-5%) HP:0001025
33 vasculitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0002633
34 memory impairment 58 31 occasional (7.5%) Occasional (29-5%) HP:0002354
35 cutis marmorata 58 31 occasional (7.5%) Occasional (29-5%) HP:0000965
36 retinal hemorrhage 58 31 occasional (7.5%) Occasional (29-5%) HP:0000573
37 recurrent infections 58 31 occasional (7.5%) Occasional (29-5%) HP:0002719
38 pleural effusion 58 31 occasional (7.5%) Occasional (29-5%) HP:0002202
39 diarrhea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002014
40 lymphadenopathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0002716
41 pulmonary infiltrates 58 31 occasional (7.5%) Occasional (29-5%) HP:0002113
42 elevated erythrocyte sedimentation rate 58 31 occasional (7.5%) Occasional (29-5%) HP:0003565
43 pedal edema 58 31 occasional (7.5%) Occasional (29-5%) HP:0010741
44 multifocal epileptiform discharges 58 31 occasional (7.5%) Occasional (29-5%) HP:0010841
45 cryoglobulinemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0100778

MGI Mouse Phenotypes related to Waldenstroem's Macroglobulinemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.77 BIRC3 BTK CCND1 CD40 CD40LG HAS1
2 immune system MP:0005387 9.44 BIRC3 BTK CCND1 CD40 CD40LG HAS1

Drugs & Therapeutics for Waldenstroem's Macroglobulinemia

Drugs for Waldenstroem's Macroglobulinemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 229)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Chlorambucil Approved Phase 3 305-03-3 2708
2
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
3
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
4
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
5 Antimitotic Agents Phase 3
6 Tubulin Modulators Phase 3
7
Liposomal doxorubicin Phase 3 31703
8
protease inhibitors Phase 3
9 HIV Protease Inhibitors Phase 3
10
belimumab Approved Phase 2 356547-88-1 5957 10451420
11
Mesna Approved, Investigational Phase 2 3375-50-6 598
12
Iodine Approved, Investigational Phase 2 7553-56-2 807
13
Erythromycin Approved, Investigational, Vet_approved Phase 2 114-07-8 12560
14
Pentostatin Approved, Investigational Phase 2 53910-25-1 40926 439693
15
Adenosine Approved, Investigational Phase 2 58-61-7 60961
16
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
17
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
18
Ifosfamide Approved Phase 1, Phase 2 3778-73-2 3690
19
Deferasirox Approved, Investigational Phase 2 201530-41-8 5493381 214348
20
Iron Approved Phase 2 7439-89-6 23925 29936
21
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 6857599 43805
22
Atorvastatin Approved Phase 2 134523-00-5 60823
23
Methylcobalamin Approved, Investigational Phase 1, Phase 2 13422-55-4
24
Hydroxocobalamin Approved Phase 1, Phase 2 13422-51-0 11953898 15589840
25
Zanubrutinib Approved, Investigational Phase 2 1691249-45-2
26
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
27
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
28
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
29 Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
30
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
31
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
32
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
33
Acetaminophen Approved Phase 2 103-90-2 1983
34
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
35
Promethazine Approved, Investigational Phase 2 60-87-7 4927
36
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
37
nivolumab Approved Phase 1, Phase 2 946414-94-4
38
Treosulfan Approved, Investigational Phase 2 299-75-2 9296
39
rituximab Approved Phase 2 174722-31-7 10201696
40
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
41
Venetoclax Approved, Investigational Phase 2 1257044-40-8 49846579
42
Obinutuzumab Approved, Investigational Phase 2 949142-50-1
43
Daratumumab Approved Phase 2 945721-28-8
44
Ixazomib Approved, Investigational Phase 2 1072833-77-2
45
Ichthammol Approved Phase 1, Phase 2 8029-68-3
46
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177 70789204
47
Sodium citrate Approved, Investigational Phase 2 68-04-2
48
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
49
Acyclovir Approved Phase 2 59277-89-3 2022
50
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4

Interventional clinical trials:

(show top 50) (show all 301)
# Name Status NCT ID Phase Drugs
1 The Efficacy of Cyclophosphamide Plus Dexamethasone Combinated With Rituximab or Bortezomib for the Newly Diagnosed Waldenström Macroglobulinemia - a Prospective Multicentre Randomized Control Trial From China Unknown status NCT02844322 Phase 4 Bortezomib;Rituximab
2 The Efficacy of Thalidomide Plus Cyclophosphamide and Dexamethasone Following by Thalidomide and Prednisone Maintenance Therapy for the Newly Diagnosed Waldenström Macroglobulinemia - a Prospective Multicentre Phase Ⅳ Trial From China Unknown status NCT02844309 Phase 4 Thalidomide
3 Autologous Stem-cell Transplantation Versus Conventional Chemotherapy for High Risk Waldenström Macroglobulinemia - a Prospective Multicentre Phase Ⅳ Trial From China Unknown status NCT02844361 Phase 4
4 Rituximab (RTX) Therapy in Steroid Resistant Patients or Patients Relapsing After Intravenous Steroids With Active TAO Unknown status NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
5 A Single Arm, Multicenter, Phase 4 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) in Chinese Subjects With Relapse or Refractory Waldenström's Macroglobulinemia Recruiting NCT04042376 Phase 4 Ibrutinib
6 Randomized Trial Comparing the Efficacy of Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia,Lymphoplasmacytic Lymphoma or Splenic Marginal Zone Lymphoma Completed NCT00566332 Phase 3 Chlorambucil;Fludarabine
7 iNNOVATE Study: A Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study of Ibrutinib or Placebo in Combination With Rituximab in Subjects With Waldenström's Macroglobulinemia Completed NCT02165397 Phase 3 Ibrutinib;Placebo;Rituximab
8 A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies Completed NCT00075478 Phase 3 Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine
9 A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial Completed NCT01231412 Phase 3 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
10 A Randomised Trial of Chlorambucil Versus Fludarabine as Initial Therapy of Waldenström's Macroglobulinaemia and Splenic Lymphoma With Villous Lymphocytes Completed NCT00608374 Phase 3 chlorambucil;fludarabine phosphate
11 First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.A Multicentre, Phase III Randomized Study by the PLRG. Completed NCT00801281 Phase 3 Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone 1;Prednisone 2
12 Efficacy and Safety of Ibrutinib in Patients With Chronic Lymphocytic Leukemia and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers Recruiting NCT02991638 Phase 3 Ibrutinib
13 Randomised Phase II/III Study of Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia Recruiting NCT04061512 Phase 2, Phase 3 Dexamethasone, cyclophosphamide, rituximab;Rituximab, ibrutinib
14 Efficacy of First Line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for Patients With Waldenström's Macroglobulinemia Active, not recruiting NCT01788020 Phase 3 Dexamethasone, Rituximab, Cyclophosphamide;Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib
15 A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM) Active, not recruiting NCT03053440 Phase 3 BGB-3111;Ibrutinib
16 A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study Enrolling by invitation NCT01804686 Phase 3 PCI-32765 (Ibrutinib)
17 Efficacy of Carfilzomib in Combination With Ibrutinib in Waldenström's Macroglobulinemia (CZAR-1) Not yet recruiting NCT04263480 Phase 3 Carfilzomib + Ibrutinib;Ibrutinib
18 A Phase 2 Study to Evaluate the Efficacy of Bortezomib in Patients With De-novo Waldenstrom's Macroglobulinemia and Lymphoplasmacytic Lymphoma Unknown status NCT03335098 Phase 2 Bortezomib
19 A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531 Unknown status NCT01813227 Phase 2 Carfilzomib;Rituximab;Dexamethasone
20 Study of Safety, Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia Unknown status NCT02981745 Phase 1, Phase 2 CT-1530
21 Phase II Study of Combination Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia: A Multicenter Trial of the European Myeloma Network Unknown status NCT01046006 Phase 2 Bortezomib, Rituximab, Dexamethasone
22 Phase I/II Study to Assess the Safety and Efficacy of Low Doses of Beta LT in Patients With Waldenstrom's Macroglobulinemia Unknown status NCT00041379 Phase 1, Phase 2 beta alethine
23 Velcade/Dexamethasone/Cyclophosphamide(PCD) Versus Rituximab /Dexamethasone/Cyclophosphamide(RCD) for the Treatment of Patients With Waldenstrom's Macroglobulinemia Unknown status NCT02971982 Phase 1, Phase 2 rituximab /Dexamethasone/cyclophosphamide;Velcade/Dexamethasone/cyclophosphamide
24 A Single Arm, Phase II Study of the Anti-Blys Monoclonal Antibody, Belimumab in Symptomatic Waldenstroms Macroglobulinaemia Unknown status NCT01142011 Phase 2 Belimumab
25 A Phase 1b/2 Investigator Initiated Study of RCHOP in Combination With Selinexor (KPT-330) in B Cell Non-Hodgkin's Lymphoma Unknown status NCT03147885 Phase 1, Phase 2 Selinexor
26 Phase 1b/2, Multicenter, Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies Completed NCT01416428 Phase 1, Phase 2 oprozomib
27 Phase I/II Study of G3139 (Genasense) in Patients With Waldenstrom's Macroglobulinemia Completed NCT00062244 Phase 1, Phase 2
28 An Extension Study to Evaluate the Long-Term Safety, Tolerability, and Clinical Activity of IMO-8400 in Patients With Relapsed or Refractory Waldenström's Macroglobulinemia Who Completed Study 8400-401 Completed NCT02363439 Phase 1, Phase 2 IMO-8400 0.6 mg/kg/wk or 1.2 mg/kg twice weekly
29 A Phase IIA Trial Testing the Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia Completed NCT00777738 Phase 2 BORTEZOMIB
30 A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia Completed NCT00811733 Phase 2
31 A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia Completed NCT00398710 Phase 2 Perifosine
32 A Phase 2, Single-Arm, Open-Label, Multicenter Study of Bruton's Tyrosine Kinase (BTK) Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM) Completed NCT03332173 Phase 2 BGB-3111
33 Phase II Study of Campath-1H in Patients With Lymphoplasmacytic Lymphoma (Waldenstrom's Macroglobulinemia) Completed NCT00142181 Phase 2 Campath-1H
34 Phase II Study of Combination Rituxan (Rituximab, Mabthera) and Fludarabine Therapy in Lymphoplasmacytic Lymphoma (Waldenstrom's Macroglobulinemia) Completed NCT00020800 Phase 2 fludarabine phosphate
35 A Multicenter Phase I/II Dose Escalation Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia Completed NCT02302469 Phase 1, Phase 2 Revlimid
36 UARK 99-006, A Phase II Pilot Study of Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia Completed NCT00083707 Phase 2 Thalidomide
37 Phase II Study of Combination Bortezomib (Velcade PS-341) and Rituximab in Patients With Previously Untreated and Relapsed/Refractory Waldenstrom's Macroglobulinemia Completed NCT00422799 Phase 2 Bortezomib;Rituximab
38 A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia Completed NCT00422656 Phase 2 Perifosine
39 A Phase II Study of the Combination Bortezomib (Velcade, PS-341), Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia Completed NCT00250926 Phase 2 Bortezomib;Dexamethasone;Rituximab
40 Phase II Study of Sildenafil Citrate in Waldenstrom's Macroglobulinemia Completed NCT00165295 Phase 2 Sildenafil citrate (Viagra)
41 Phase II Study of Velcade in Waldenstrom's Macroglobulinemia Completed NCT00142129 Phase 2 Bortezomib (Velcade)
42 Phase II Study of Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia Completed NCT00142116 Phase 2 Thalidomide;Rituximab
43 Carfilzomib, Rituximab, and Dexamethasone (CaRD) in Waldenstrom's Macroglobulinemia Completed NCT01470196 Phase 2 Dexamethasone;Carfilzomib;Rituximab
44 An Open Label, Multicenter Phase 2 Study of Single-Agent Enzastaurin HCl in Previously Treated Waldenstrom's Macroglobulinemia or Multiple Myeloma Completed NCT00718419 Phase 2 Enzastaurin
45 Phase II Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia Completed NCT02400437 Phase 2 Ixazomib;Dexamethasone;Rituximab
46 Fase II Study With Bortezomib, Rituximab and Bendamustin-BRB- for Non-Hodgkin Lymphoplasmocytic Lymphoma/Waldenstrom Macroglobulinemia's Patients at First Relapse Completed NCT02371148 Phase 2 Bortezomib-Rituximab-Bendamustine
47 Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765), in Waldenstrom's Macroglobulinemia Completed NCT01614821 Phase 2 PCI-32765
48 Phase II Study of Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia Completed NCT00976248 Phase 2 RAD001
49 Phase II Trial of LBH589 (Panobinostat) in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia Completed NCT00936611 Phase 2 LBH589
50 A Phase II Study Of PS-341 (NSC 681239) In Patients With Untreated Or Relapsed Waldenstrom's Macroglobulinemia Completed NCT00045695 Phase 2 bortezomib

Search NIH Clinical Center for Waldenstroem's Macroglobulinemia

Cochrane evidence based reviews: waldenstrom macroglobulinemia

Genetic Tests for Waldenstroem's Macroglobulinemia

Anatomical Context for Waldenstroem's Macroglobulinemia

MalaCards organs/tissues related to Waldenstroem's Macroglobulinemia:

40
Bone Marrow, B Cells, Heart, Spleen, T Cells, Liver, Myeloid

Publications for Waldenstroem's Macroglobulinemia

Articles related to Waldenstroem's Macroglobulinemia:

(show top 50) (show all 341)
# Title Authors PMID Year
1
microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia. 47
19074725 2009
2
Inherited and acquired variations in the hyaluronan synthase 1 (HAS1) gene may contribute to disease progression in multiple myeloma and Waldenstrom macroglobulinemia. 54 61
18815290 2008
3
Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia. 54 61
18452095 2008
4
Genomewide linkage screen for Waldenstrom macroglobulinemia susceptibility loci in high-risk families. 54 61
16960805 2006
5
Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas. 54 61
16983704 2006
6
Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. 61 54
15493038 2004
7
Clonotypic IgM V/D/J sequence analysis in Waldenstrom macroglobulinemia suggests an unusual B-cell origin and an expansion of polyclonal B cells in peripheral blood. 54 61
14764523 2004
8
Peripheral neuropathy in IgM monoclonal gammopathy and Wäldenstrom's macroglobulinemia: a frequent complication in elderly males with low MAG-reactive serum monoclonal component. 54 61
7504399 1994
9
Multimodal imaging of two cases of retinal vein occlusion secondary to Waldenstrom macroglobulinemia. 61
33535793 2021
10
Bruton Tyrosine Kinase Inhibitors in Waldenstrom Macroglobulinemia: Unprecedented Clinical Activity and Promising Future Directions. 61
33444081 2021
11
Treatment facility volume and patient outcomes in Waldenstrom macroglobulinemia. 61
33054437 2021
12
Severe and Irreversible Pancytopenia Associated With SARS-CoV-2 Bone Marrow Infection in a Patient With Waldenstrom Macroglobulinemia. 61
33563581 2021
13
The Eyes Cannot See What the Mind Does Not Know: Endocrinological Side Effects of Ibrutinib. 61
33428844 2020
14
Novel tumor-targeted liposomes comprised of an MDM2 antagonist plus proteasome inhibitor display anti-tumor activity in a xenograft model of bortezomib-resistant Waldenstrom macroglobulinemia. 61
32558607 2020
15
MYD88 L265P Elicits Mutation-specific Ubiquitination to Drive NF-κB Activation and Lymphomagenesis. 61
33025009 2020
16
Catastrophic Antiphospholipid Syndrome as the Initial Presentation of Waldenstrom Macroglobulinemia. 61
32532610 2020
17
Increased glutathione utilization augments tumor cell proliferation in Waldenstrom Macroglobulinemia. 61
32763516 2020
18
Clinical Reasoning: Multifocal neuropathies in a patient with Waldenstrom macroglobulinemia and prior borreliosis. 61
32527969 2020
19
Waldenstrom's macroglobulinemia in the era of immunotherapy. 61
31960730 2020
20
Cutaneous amyloidosis as the first presentation of Waldenstrom macroglobulinemia. 61
32874445 2020
21
Health-related quality of life in Waldenstrom Macroglobulinemia and IgM-related disorders: A single institution experience. 61
31852014 2020
22
Hyperviscosity Syndrome in Paraprotein Secreting Conditions Including Waldenstrom Macroglobulinemia. 61
32509586 2020
23
JL1 Antigen Expression on Bone Marrow Lymphoma Cells from Patients With Non-Hodgkin Lymphoma. 61
31432632 2020
24
Prognostic Factors in Patients with Low-Grade Nonhodgkin Lymphoma. 61
32158088 2020
25
Deepening of response after completing rituximab-containing therapy in patients with Waldenstrom macroglobulinemia. 61
31868242 2019
26
What is new in the treatment of Waldenstrom macroglobulinemia? 61
31591468 2019
27
Development of Central Nervous System Vasculitis in a Patient with Waldenstrom Macroglobulinemia: A Rare Presentation with Poor Prognosis. 61
31824806 2019
28
Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later. 61
30993606 2019
29
Bortezomib-based chemotherapy can improve renal and tubular functions in patients with light chain-associated Fanconi syndrome. 61
30511139 2019
30
Distal Ileal Ulcers as Gastrointestinal Manifestation of Waldenstrom Macroglobulinemia. 61
31616739 2019
31
Ibrutinib in the management of Waldenstrom macroglobulinemia. 61
29996737 2019
32
Serum markers in the differential diagnosis of Waldenstrom macroglobulinemia and other IgM monoclonal gammopathies. 61
30485557 2019
33
Waldenstrom macroglobulinemia retinopathy. Waldenstrom and eyes. 61
30679119 2019
34
Central Nervous System Involvement by Waldenstrom Macroglobulinemia: A Case Report of the Bing-Neel Syndrome. 61
31001436 2019
35
UNUSUAL SEROUS RETINAL DETACHMENT IN A PATIENT WITH WALDENSTROM MACROGLOBULINEMIA: A CASE REPORT. 61
28106626 2019
36
Evaluation of Serum Free Light Chain in Diagnosis and Monitoring of Plasma Cell Disorders. 61
32421964 2019
37
Waldenström Macroglobulinemia: Unusual Presentation With Cast Nephropathy/Light Chain Tubulopathy. 61
30799965 2019
38
How I treat elderly patients with plasma cell dyscrasias. 61
30568029 2018
39
Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients. 61
30366921 2018
40
SEROUS MACULAR DETACHMENT ASSOCIATED WITH WALDENSTROM MACROGLOBULINEMIA MANAGED WITH IBRUTINIB: A CASE REPORT AND NEW INSIGHTS INTO PATHOGENESIS. 61
30531550 2018
41
A Case of Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma With Lung Lesion. 61
30239460 2018
42
Prediction of immunoglobulin M reduction via therapeutic dose of simple plasma exchange and double filtration plasmapheresis using membrane separation in patients with hyperviscosity syndrome caused by Waldenstrom macroglobulinemia. 61
30188580 2018
43
Loss of TNFAIP3 enhances MYD88L265P-driven signaling in non-Hodgkin lymphoma. 61
30301877 2018
44
Morphea associated with primary biliary cirrhosis and Waldenstrom macroglobulinemia: Response to rituximab. 61
30246126 2018
45
Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia. 61
30104397 2018
46
Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. 61
29610969 2018
47
[Research Progress on Diagnosis and Treatment of B Cell Chronic Lymphoproliferative Disease--Review]. 61
30111434 2018
48
Waldenstrom macroglobulinemia involving the superior rectus muscle. 61
29780960 2018
49
A safety profile of medications used to treat Waldenström's macroglobulinemia. 61
29768934 2018
50
A Patient with Artifactually Low Serum High Density Lipoprotein Cholesterol Due to Waldenstrom Macroglobulinemia. 61
30181932 2018

Variations for Waldenstroem's Macroglobulinemia

Cosmic variations for Waldenstroem's Macroglobulinemia:

9 (show top 50) (show all 133)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM144053685 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.637G>A p.E213K 17:7674861-7674861 0
2 COSM145024607 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.370T>A p.Y124N 17:7675125-7675125 0
3 COSM144345367 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.553G>A p.E185K 17:7674861-7674861 0
4 COSM143162240 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.10T>A p.Y4N 17:7675125-7675125 0
5 COSM106095757 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.670G>A p.E224K 17:7674861-7674861 0
6 COSM106061123 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.581T>G p.L194R 17:7674950-7674950 0
7 COSM144021454 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.548T>G p.L183R 17:7674950-7674950 0
8 COSM93228799 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.670G>A p.E224K 17:7674861-7674861 0
9 COSM105627347 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 0
10 COSM87905987 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 0
11 COSM112259728 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 0
12 COSM143163611 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.104T>G p.L35R 17:7674950-7674950 0
13 COSM142842304 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 0
14 COSM105673488 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.670G>A p.E224K 17:7674861-7674861 0
15 COSM143950762 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.104T>G p.L35R 17:7674950-7674950 0
16 COSM145057596 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.553G>A p.E185K 17:7674861-7674861 0
17 COSM111767327 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.581T>G p.L194R 17:7674950-7674950 0
18 COSM144019934 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.454T>A p.Y152N 17:7675125-7675125 0
19 COSM143984355 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.193G>A p.E65K 17:7674861-7674861 0
20 COSM144092925 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.104T>G p.L35R 17:7674950-7674950 0
21 COSM144315552 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.370T>A p.Y124N 17:7675125-7675125 0
22 COSM121884065 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.91T>A p.Y31N 17:7675125-7675125 0
23 COSM143379413 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.464T>G p.L155R 17:7674950-7674950 0
24 COSM93190243 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 0
25 COSM145026000 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.464T>G p.L155R 17:7674950-7674950 0
26 COSM87907551 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.581T>G p.L194R 17:7674950-7674950 0
27 COSM122741542 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.185T>G p.L62R 17:7674950-7674950 0
28 COSM144120694 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.193G>A p.E65K 17:7674861-7674861 0
29 COSM111765354 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 0
30 COSM144658360 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.370T>A p.Y124N 17:7675125-7675125 0
31 COSM121923690 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.274G>A p.E92K 17:7674861-7674861 0
32 COSM144316769 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.464T>G p.L155R 17:7674950-7674950 0
33 COSM111802343 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.670G>A p.E224K 17:7674861-7674861 0
34 COSM143413054 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.553G>A p.E185K 17:7674861-7674861 0
35 COSM106059625 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 0
36 COSM143377649 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.370T>A p.Y124N 17:7675125-7675125 0
37 COSM122740310 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.91T>A p.Y31N 17:7675125-7675125 0
38 COSM122277937 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.91T>A p.Y31N 17:7675125-7675125 0
39 COSM112296873 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.670G>A p.E224K 17:7674861-7674861 0
40 COSM87949396 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.670G>A p.E224K 17:7674861-7674861 0
41 COSM122781432 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.274G>A p.E92K 17:7674861-7674861 0
42 COSM142871029 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.670G>A p.E224K 17:7674861-7674861 0
43 COSM142566548 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.370T>A p.Y124N 17:7675125-7675125 0
44 COSM122314745 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.274G>A p.E92K 17:7674861-7674861 0
45 COSM142567868 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.464T>G p.L155R 17:7674950-7674950 0
46 COSM112261074 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.581T>G p.L194R 17:7674950-7674950 0
47 COSM144696301 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.553G>A p.E185K 17:7674861-7674861 0
48 COSM93192035 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.581T>G p.L194R 17:7674950-7674950 0
49 COSM144660214 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.464T>G p.L155R 17:7674950-7674950 0
50 COSM105628829 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.581T>G p.L194R 17:7674950-7674950 0

Expression for Waldenstroem's Macroglobulinemia

Search GEO for disease gene expression data for Waldenstroem's Macroglobulinemia.

Pathways for Waldenstroem's Macroglobulinemia

Pathways related to Waldenstroem's Macroglobulinemia according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.45 ZAP70 PTPRC CD40LG CD40 BTK
2
Show member pathways
12.4 ZAP70 PTPRC MYD88 IRF4 CD40LG
3
Show member pathways
12.32 ZAP70 PTPRC CD40 BTK
4 12.29 MIR9-1 MIR494 MIR206 MIR155 CCND1
5
Show member pathways
12.27 ZAP70 PTPRC CD40LG CD40
6 12.21 ZAP70 PTPRC PAX5 MYD88 IRF4 CD40LG
7
Show member pathways
12.09 MYD88 CD40LG CD40 BIRC3
8 11.91 PTPRC MAG CD40LG CD40
9 11.64 PAX5 CCND1 BIRC3
10 11.61 PTPRC MS4A1 IRF4
11
Show member pathways
11.6 CD40LG CD40 BIRC3
12 11.53 PAX5 CD40LG CD40
13
Show member pathways
11.5 CD40LG CCND1 BIRC3
14 11.45 ZAP70 MYD88 CD40LG CD40 BTK BIRC3
15 11.35 MYD88 CD40LG CD40
16 11.06 ZAP70 CD40LG CD40
17 11 PTPRC CD40LG CD40
18 10.91 CD40LG CD40 BIRC3
19 10.6 ZAP70 PTPRC CD40LG CD40 BTK
20 10.45 MIR206 MAG

GO Terms for Waldenstroem's Macroglobulinemia

Cellular components related to Waldenstroem's Macroglobulinemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane raft GO:0045121 9.02 ZAP70 PTPRC MAG BTK BIRC3

Biological processes related to Waldenstroem's Macroglobulinemia according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of tumor necrosis factor production GO:0032760 9.76 PTPRC MYD88 MIR206
2 gene silencing by miRNA GO:0035195 9.73 MIR9-1 MIR542 MIR494 MIR206 MIR184 MIR155
3 cellular response to mechanical stimulus GO:0071260 9.71 MYD88 MAG CD40
4 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.71 MYD88 CD40LG CD40 BTK
5 B cell differentiation GO:0030183 9.7 PTPRC MS4A1 CD40LG
6 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.61 MIR494 MIR206 MIR155
7 negative regulation of cell adhesion molecule production GO:0060354 9.59 MIR206 MIR155
8 negative regulation of microglial cell activation GO:1903979 9.58 PTPRC MIR155
9 cellular response to oxidised low-density lipoprotein particle stimulus GO:0140052 9.57 MYD88 MIR155
10 negative thymic T cell selection GO:0045060 9.56 ZAP70 PTPRC
11 positive thymic T cell selection GO:0045059 9.55 ZAP70 PTPRC
12 T cell activation GO:0042110 9.54 ZAP70 PTPRC IRF4
13 positive regulation of isotype switching to IgG isotypes GO:0048304 9.51 PTPRC CD40
14 positive regulation of interleukin-12 production GO:0032735 9.5 MIR155 CD40LG CD40
15 positive regulation of alpha-beta T cell proliferation GO:0046641 9.49 ZAP70 PTPRC
16 CD40 signaling pathway GO:0023035 9.48 CD40LG CD40
17 regulation of immunoglobulin production GO:0002637 9.46 CD40LG CD40
18 defense response to protozoan GO:0042832 9.33 MYD88 IRF4 CD40
19 B cell activation GO:0042113 9.26 ZAP70 MS4A1 CD40 BTK
20 B cell proliferation GO:0042100 8.92 PTPRC MS4A1 CD40LG CD40

Molecular functions related to Waldenstroem's Macroglobulinemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 8.92 MIR9-1 MIR494 MIR206 MIR155

Sources for Waldenstroem's Macroglobulinemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....